Recent News

• 12.12.2025 - Cadrenal’s Quiet Expansion Play Is Starting to Get Loud
• 12.12.2025 - Cadrenal’s Anticoagulation Platform Is Expanding in a $40 Billion Market
• 12.11.2025 - Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)
• 12.01.2025 - Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors
• 11.19.2025 - Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida’s Executive of the Year Award
• 11.10.2025 - Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Recent Filings

• 12.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.03.2025 - 3 Initial statement of beneficial ownership of securities
• 12.01.2025 - EX-99.1 EX-99.1
• 12.01.2025 - 8-K Current report
• 11.18.2025 - 8-K Current report
• 11.18.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 11.10.2025 - 8-K Current report
• 11.10.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.10.2025 - EX-99.1 EX-99.1
• 10.28.2025 - 4 Statement of changes in beneficial ownership of securities